Quoin Pharmaceuticals, Ltd. (NasdaqCM:QNRX) is looking for M&A. Michael Myers, Chief Executive Officer said, "We remain diligently focused on pursuing M&A activities and are targeting executing at least one such transaction by year-end".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.745 USD | -4.03% | +8.74% | -84.81% |
Mar. 15 | Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating | MT |
Mar. 14 | Quoin Pharmaceuticals Seeks M&A Opportunities | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-84.81% | 2.86M | |
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B |
- Stock Market
- Equities
- QNRX Stock
- News Quoin Pharmaceuticals, Ltd.
- Quoin Pharmaceuticals Limited Seeks M&A